Clinical Trials

Unlocking the Potential of Immunotherapy

To learn more about these compounds, choose areas of interest in the table below (select all that apply).

total trials found

Phase III

Phase II

Phase I

TUMOR TYPE

TRIAL NAME

MOLECULE

PHASE III
PHASE III
PHASE II
PHASE II
PHASE I
PHASE I

PD-L1=programmed cell death ligand-1; FGFR=fibroblast growth factor receptor; PARP=poly ADP-ribose polymerase; mTORC=mammalian target of rapamycin complex; CTLA-4=cytotoxic T-lymphocyte-associated antigen-4; NSCLC=non-small cell lung cancer; EGFR=epidermal growth factor receptor; TKI=tyrosine kinase inhibitor; HNSCC=head and neck squamous cell carcinoma; STAT3=signal transducer and activator of transcription 3; GE=gastroesophageal; GITR=glucocorticoid-induced TNF receptor; A2AR=adenosine A2a receptor; TLR7/8=toll-like receptor 7/8.

References

1. Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res. 2013;19(5):997-1008. 2. AstraZeneca. Clinical trials appendix Q1 2017 results update. https://www.astrazeneca.com/content/dam/az/PDF/2017/QR1/Q1_2017_Results_Clinical_Trial_Appendix.pdf. Accessed May 10, 2017.